| |
Comparison of Hepatitis C Treatment Costs
|
| |
| |
Estimates of Net Prices and Usage in the U.S. and Other Major Markets
So why haven't federal & state officials requiring full unfettered access to HCV treatment? Because they can get away with it! In the mid 1990s AIDS activists politically embarrassed the federal govt to respond to AIDS & prior to that city, state & federal governments refused to recognize the AIDS problem including NYC Mayor Koch & Pres Reagan. I have worked with govt officials for 25 years including the FDA & they ONLY act when its politically expedient, when they are embarrassed & forced to act. Today state & federal officials have not been embarassed. All too often advocates have been quiet & work 'with' state & federal officials. Jules
New Study: Negotiated Hepatitis C Prescription Drug Costs in United States Often Lower than in Price-Controlled European Countries and Japan
WASHINGTON, Sept. 20, 2016 /PRNewswire-USNewswire/ -- A new report shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan.
"According to this comparison, conventional wisdom has underestimated the ability of large, sophisticated, private-sector payers to reduce costs and improve access to high cost drugs," said PCMA President and CEO Mark Merritt. The proportion of infected people who receive Hepatitis C treatment in Part D was in-line with the average treatment rate for other countries examined in the study. But unlike Part D, both drug prices and access to treatments have been determined through government mechanisms in other countries…..http://www.prnewswire.com/news-releases/new-study-negotiated-hepatitis-c-prescription-drug-costs-in-united-states-often-lower-than-in-price-controlled-european-countries-and-japan-300330992.html
---------------------------------------------
Comparison of Hepatitis C Treatment Costs
Estimates of Net Prices and Usage in the U.S. and Other Major Markets
The study was conducted independently by the IMS Institute with funding support from the Pharmaceutical Care Management Association (PCMA), the national association representing America's pharmacy benefit managers (PBMs).
http://www.imshealth.com/files/web/IMSH Institute/Healthcare Briefs/IIHI_Comparison_of_HepatitisC_Treatment_Costs.pdf
"In VA Zepatier and Harvoni are $17k, a little birdie told me", Jules. My understanding is medicaid pricing is much lower in the USA than the $50k cited here in this report, it is more like $25,000-$40,000 for medicaids in the USA, recent discounts & rebates have brought prices down for medicaids to this $25-40k level.
Net prices in Italy were not specifically disclosed but media reports indicated "price/volume concessions" had been agreed, and that net prices would be at or below 37,000 euros. This value was employed in the analysis.
|
|
| |
| |
|
|
|
